KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

nhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs (Balak et al., 2006; Kosaka et al., 2006; Rudin e...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Krall, Elsa B, Munoz, Diana M, Ilic, Nina, Niederst, Matthew J, Yu, Kristine, Ruddy, David A, Redig, Amanda J, Gainor, Justin F, Williams, Juliet A, Asara, John M, Janne, Pasi A, Shaw, Alice T, McDonald III, Robert E, Engelman, Jeffrey A, Stegmeier, Frank, Schlabach, Michael R, Wang, Belinda, Raghavan, Srivatsan, Aguirre, Andrew J., Kim, Jong Wook, Doench, John Gerard, Hahn, William
Beste egile batzuk: Broad Institute of MIT and Harvard
Formatua: Artikulua
Hizkuntza:en_US
Argitaratua: eLife Sciences Publications, Ltd. 2017
Sarrera elektronikoa:http://hdl.handle.net/1721.1/109867
https://orcid.org/0000-0001-5367-2546

Internet

http://hdl.handle.net/1721.1/109867
https://orcid.org/0000-0001-5367-2546

Antzeko izenburuak